SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Eva Schaeffer, Andrea Pilotto, Daniela Berg, Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease, CNS Drugs, 2014, 28, 12, 1155

    CrossRef

  2. 2
    Shin-ichi Uchida, Takako Kadowaki-Horita, Tomoyuki Kanda, Adenosine Receptors in Neurology and Psychiatry, 2014,

    CrossRef

  3. 3
    Jee Young Lee, Sohee Oh, Jong Min Kim, Ji Sun Kim, Eungseok Oh, Hee-Tae Kim, Beom S. Jeon, Jin Whan Cho, Intravenous amantadine on freezing of gait in Parkinson’s disease: a randomized controlled trial, Journal of Neurology, 2013, 260, 12, 3030

    CrossRef

  4. 4
    Lukas Wanka, Khalid Iqbal, Peter R. Schreiner, The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives, Chemical Reviews, 2013, 113, 5, 3516

    CrossRef

  5. 5
    Thien Lim, Kelvin Chou, Hubert Fernandez, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  6. 6
    Thien Thien Lim, Kelvin L. Chou, Hubert H. Fernandez, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  7. 7
    Per Svenningsson, Eric Westman, Clive Ballard, Dag Aarsland, Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment, The Lancet Neurology, 2012, 11, 8, 697

    CrossRef

  8. 8
    Mireille Basselin, Epolia Ramadan, Stanley I. Rapoport, Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans, Brain Research Bulletin, 2012, 87, 2-3, 154

    CrossRef

  9. 9
    Cornelius Rainer Pawlak, Fu-Shih Chen, Fu-Ying Wu, Ying-Jui Ho, Potential of D-cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson's disease and studies that need to be performed before clinical trials, The Kaohsiung Journal of Medical Sciences, 2012, 28, 8, 407

    CrossRef

  10. 10
    Susan Duty, Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease, CNS Drugs, 2012, 26, 12, 1017

    CrossRef

  11. 11
    Bernardino Ossola, Nadia Schendzielorz, Shih-Heng Chen, Gary S. Bird, Raimo K. Tuominen, Pekka T. Männistö, Jau-Shyong Hong, Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GNDF in astroglia, Neuropharmacology, 2011, 61, 4, 574

    CrossRef

  12. 12
    Paolo Barone, Dag Aarsland, David Burn, Murat Emre, Jaime Kulisevsky, Daniel Weintraub, Cognitive impairment in nondemented Parkinson's disease, Movement Disorders, 2011, 26, 14
  13. 13
    A. Yu. Yablonskaya, N. V. Fedorova, M. E. Belgusheva, Effects of Amantadine Sulfate on Cognitive Impairments in Patients with Parkinson’s Disease, Neuroscience and Behavioral Physiology, 2011, 41, 6, 567

    CrossRef

  14. 14
    Ying-Jui Ho, Shih-Chun Ho, Cornelius Rainer Pawlak, Kuei-Ying Yeh, Effects of d-cycloserine on MPTP-induced behavioral and neurological changes: Potential for treatment of Parkinson's disease dementia, Behavioural Brain Research, 2011, 219, 2, 280

    CrossRef

  15. 15
    Karen Marder, Cognitive impairment and dementia in Parkinson's disease, Movement Disorders, 2010, 25, S1
  16. 16
    David Devos, L. Defebvre, R. Bordet, Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease, Fundamental & Clinical Pharmacology, 2010, 24, 4
  17. 17
    D. Devos, R. Bordet, L. Defebvre, Hypothèses pharmacologiques et prise en charge thérapeutique des troubles de la marche de la maladie de Parkinson, Revue Neurologique, 2010, 166, 2, 168

    CrossRef

  18. 18
    An-Li Wang, Ying-Ming Liou, Cornelius Rainer Pawlak, Ying-Jui Ho, Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats, Behavioural Brain Research, 2010, 208, 1, 38

    CrossRef

  19. 19
    Angie A Kehagia, Roger A Barker, Trevor W Robbins, Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease, The Lancet Neurology, 2010, 9, 12, 1200

    CrossRef

  20. 20
    Dag Aarsland, Martin Wilhelm Kurz, The epidemiology of dementia associated with Parkinson disease, Journal of the Neurological Sciences, 2010, 289, 1-2, 18

    CrossRef

  21. 21
    Dag Aarsland, Martin Wilhelm Kurz, The Epidemiology of Dementia Associated with Parkinson's Disease, Brain Pathology, 2010, 20, 3
  22. 22
    David J. Burn, The Treatment of Cognitive Impairment Associated with Parkinson's Disease, Brain Pathology, 2010, 20, 3
  23. 23
    I. V. Litvinenko, M. M. Odinak, V. I. Mogil’naya, S. V. Perstnev, Use of Memantine (akatinol) for the Correction of Cognitive Impairments in Parkinson’s Disease Complicated by Dementia, Neuroscience and Behavioral Physiology, 2010, 40, 2, 149

    CrossRef

  24. 24
    David John Burn, MOVEMENT DISORDERS 4, 2010,

    CrossRef

  25. 25
    Gwyn M. Vernon, Parkinson Disease and the Nurse Practitioner: Diagnostic and Management Challenges, The Journal for Nurse Practitioners, 2009, 5, 3, 195

    CrossRef

  26. 26
    Dag Aarsland, Mona K Beyer, Martin W Kurz, Dementia in Parkinsonʼs disease, Current Opinion in Neurology, 2008, 21, 6, 676

    CrossRef

  27. 27
    Julian W. Tang, Karry L.K. Ngai, Jasper C.L. Wong, Wai Y. Lam, Paul K.S. Chan, Emergence of adamantane-resistant influenza A(H3N2) viruses in Hong Kong between 1997 and 2006, Journal of Medical Virology, 2008, 80, 5
  28. 28
    Nir Giladi, Medical treatment of freezing of gait, Movement Disorders, 2008, 23, S2
  29. 29
    Current awareness in geriatric psychiatry, International Journal of Geriatric Psychiatry, 2007, 22, 5
  30. 30
    Jyh-Gong Gabriel Hou, Eugene C Lai, Non-motor Symptoms of Parkinson's Disease, International Journal of Gerontology, 2007, 1, 2, 53

    CrossRef

  31. 31
    Alex Rajput, Can amantadine therapy delay the onset of dementia in Parkinson's disease?, Nature Clinical Practice Neurology, 2006, 2, 12, 648

    CrossRef

  32. 32
    David J. Burn, Clinical Features of Dementia Associated with Parkinson's Disease and Dementia with Lewy Bodies,
  33. 33
    Susan H. Fox, Jonathan M. Brotchie, Non-Dopaminergic Approaches to the Treatment of Parkinson's Disease,
  34. 34
    Murat Emre, Treatment of Dementia Associated with Parkinson's Disease,